Select therapeutic use:

CHF and arrhythmias:

Indications for: TRULICITY

As adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). 

Adult Dosage:

Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. Initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.

Children Dosage:

Not established.

TRULICITY Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

TRULICITY Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.

TRULICITY Classification:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

TRULICITY Interactions:

Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

Adverse Reactions:

Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.

Metabolism:

Protein catabolism pathways.

Drug Elimination:

Half-life: ~5 days.

Generic Drug Availability:

NO

How Supplied:

Single-dose pen—4

Diabetes:

Indications for: TRULICITY

As adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). 

Limitations of Use:

Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes mellitus. Not recommended in patients with severe GI disease (including severe gastroparesis).

Adult Dosage:

Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.

Children Dosage:

<10yrs: not established. Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥10yrs: initially 0.75mg once weekly. If additional glycemic control is needed, may increase to max 1.5mg once weekly after ≥4 weeks on the 0.75mg dose.

TRULICITY Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

TRULICITY Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.

TRULICITY Classification:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

TRULICITY Interactions:

Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

Adverse Reactions:

Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.

Metabolism:

Protein catabolism pathways.

Drug Elimination:

Half-life: ~5 days.

Generic Drug Availability:

NO

How Supplied:

Single-dose pen—4